Loading stock…

Repligen Corporation (RGEN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Repligen Corporation

RGENMarket cap $9.44BPrice $167.7

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes the tools and components used to manufacture biologic drugs, from filtration systems to bioreactor tech. Nearly every major biotech relies on its gear somewhere in the production process — it profits whether or not the drugs succeed.

In Bastion Portfolios?

52W Return+10%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-3%2

Revenue Forecast

Rev CAGR (1y)+12%7

Rev CAGR (3y)+15%8

Rev CAGR (5y)+16%9

Earnings Forecast

EPS Growth Y+1+138%10

EPS Growth Y+2+28%8

EPS Growth Y+3+34%9

Quality

Margins

EBIT Margin8%4

Net Income Margin5%4

Free Cash Flow Margin14%7

Debt

Net Debt/EBITDA-0.610

Efficiency

ROE2%2

ROA1%3

Earnings Stability55

GEAR+WEAK32

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)731

P/E Ratio (Forward 3y)471

P/BV4.54

EV Multiples

EV/EBITDA Fwd551

EV/EBIT Fwd711

Yield

Free Cash Flow Yield1.2%3

Dividend Yieldna–

Momentum

Short term

1 month return-1%7

3 month return+22%10

YTD return+2%5

Mid term

Price vs 52wHigh84%6

1 year return+11%6

Long term

3 year return+9%3

5 year return-35%2

Risk Shield

Price Risk

Beta1.42

Volatility46%4

Free Cash Flow

Free Cash Flow Margin14%7

Free Cash Flow Yield1.2%3

Quality

ROCE2%2

Earnings Stability55

Net Debt/EBITDA-0.610

02Growth

Is it actually growing, and how fast?

RGENRepligen

Revenue FY25$738M

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+138%10

EPS growth, FY27E+28%8

EPS growth, FY28E+34%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.8/10

After shrinking over the last 3 years, revenue is set to grow 15%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 34%/yr vs revenue 15%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A top-tier grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return+22%10

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+11%6

3-year return+9%3

5-year return-35%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-1%) and over three months (+22%).

WATCH

It's up 11% over the past year, but 16% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (+2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+8.9% over three years and -35% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Repligen. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RGENRepligen

Revenue FY25$738M

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+138%10

EPS growth, FY27E+28%8

EPS growth, FY28E+34%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.8/10

After shrinking over the last 3 years, revenue is set to grow 15%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 34%/yr vs revenue 15%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A top-tier grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return+22%10

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+11%6

3-year return+9%3

5-year return-35%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-1%) and over three months (+22%).

WATCH

It's up 11% over the past year, but 16% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (+2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+8.9% over three years and -35% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Repligen. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community